YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer

Y-box binding protein 1 (YB-1) is a well-known oncogene highly expressed in various cancers, including basal-like breast cancer (BLBC). Beyond its role as a transcription factor, YB-1 is newly defined as an epigenetic regulator involving RNA 5-methylcytosine. However, its specific targets and pro-cancer functions are poorly defined. Here, based on clinical database, we demonstrate a positive correlation between Kruppel-like factor 5 (KLF5) and YB-1 expression in breast cancer patients, but a negative correlation with that of Dachshund homolog 1 (DACH1). Mechanistically, YB-1 enhances KLF5 expression not only through transcriptional activation that can be inhibited by DACH1, but also by stabilizing KLF5 mRNA in a RNA 5-methylcytosine modification-dependent manner. Additionally, ribosomal S6 kinase 2 (RSK2) mediated YB-1 phosphorylation at Ser102 promotes YB-1/KLF5 transcriptional complex formation, which co-regulates the expression of BLBC specific genes, Keratin 16 (KRT16) and lymphocyte antigen 6 family member D (Ly6D), to promote cancer cell proliferation. The RSK inhibitor, LJH685, suppressed BLBC cell tumourigenesis in vivo by disturbing YB-1-KLF5 axis. Our data suggest that YB-1 positively regulates KLF5 at multiple levels to promote BLBC progression. The novel RSK2-YB-1-KLF5-KRT16/Ly6D axis provides candidate diagnostic markers and therapeutic targets for BLBC.

Automated summary

Y-box binding protein 1 (YB-1) is highly expressed in various cancers, including basal-like breast cancer (BLBC), and functions as a transcription factor and an epigenetic regulator. The study reveals a positive correlation between YB-1 and Kruppel-like factor 5 (KLF5) expression in breast cancer patients, as well as a negative correlation with Dachshund homolog 1 (DACH1) expression. Mechanistically, YB-1 enhances KLF5 expression through transcription activation and mRNA stabilization, promoting cancer cell proliferation by regulating the expression of specific genes. The phosphorylation of YB-1 by ribosomal S6 kinase 2 (RSK2) promotes the formation of YB-1/KLF5 transcriptional complex and is involved in BLBC progression. These findings suggest that the RSK2-YB-1-KLF5-KRT16/Ly6D axis may serve as potential diagnostic markers and therapeutic targets for BLBC.